Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Employee Rating

4More
TypeSubsidiary
Parent CompanyBiogen
HQNewton, MA, US
Founded2008
Websitekaryopharm.com
Cybersecurity ratingCMore
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Karyopharm Therapeutics

Sharon Shacham

Sharon Shacham

President and Chief Scientific Officer, Founder
Garen Bohlin

Garen Bohlin

Director
Brian Austad

Brian Austad

Senior Vice President, Pharmaceutical Sciences
Mikael Dolsten

Mikael Dolsten

Director
Yosef Landesman

Yosef Landesman

Senior Vice President, Research and Translational Medicine
Barry E. Greene

Barry E. Greene

Lead Director
Show more

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo
Newton, MA, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Tel Aviv-Yafo, IL
Yigal Alon St 94
Show all (3)

Karyopharm Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Revenue

Karyopharm Therapeutics's revenue was reported to be $108.09 m in FY, 2020
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

387.0k229.0k250.0k154.0k30.3m40.9m108.1m

Revenue growth, %

(41%)9%

General and administrative expense

5.9m15.9m21.6m23.9m24.9m48.8m105.4m126.4m

R&D expense

28.5m60.1m97.7m86.9m107.3m161.4m122.3m150.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

171.0k21.0k21.0k150.0k75.0k59.0k48.0k68.0k19.9m239.0k155.0k9.5m13.1m18.1m33.5m21.3m23.3m

Cost of goods sold

1.0m

Gross profit

12.1m

Gross profit Margin, %

92%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

156.0m150.6m58.4m49.7m69.0m118.0m128.9m85.9m

Accounts Receivable

7.9m

Prepaid Expenses

2.0m2.0m2.0m1.8m6.4m7.3m9.3m

Inventories

2.1m346.0k2.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

52.9m144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m101.6m83.5m75.5m168.0m202.2m103.1m82.3m

Accounts Receivable

7.9m9.3m9.6m

Prepaid Expenses

658.0k2.7m3.0m4.2m2.9m4.1m3.1m1.7m1.5m3.4m2.1m2.1m2.1m2.4m3.4m4.8m7.0m5.7m5.3m7.6m8.0m8.2m

Inventories

100.0k970.0k1.7m2.0m
USDQ3, 2013

Financial Leverage

-1.2 x
Show all financial metrics

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10
Show all operating metrics

Karyopharm Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Karyopharm Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Karyopharm Therapeutics Online and Social Media Presence

Embed Graph

Karyopharm Therapeutics Company Culture

  • Overall Culture

    B

    78/100

  • CEO Rating

    C+

    72/100

  • Compensation

    A+

    90/100

  • Diversity

    B-

    77/100

Learn more on Comparably

Karyopharm Therapeutics News and Updates

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc....

KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a fede…

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPTI

NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...

KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI

NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - July 25, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal s…

Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Karyopharm Therapeutics Inc. And Certain Of Its Senior Executives, Its Board Of Directors, And Underwriters Of Its April 2017 And May 2018 Stock Offerings

NEW YORK, July 23, 2019 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") today announced that it filed a securities class action lawsuit on behalf of its client Allegheny County Employees' Retirement System ("ACERS") against Karyopharm Therapeutics Inc. ("Karyopharm" or ..…
Show more

Karyopharm Therapeutics Blogs

Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

-- Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million --

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer

-- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership and Global Strategic Experience --

Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021

-- Conference Call Scheduled for Monday, May 3, 2021, at 8:30 a.m. ET --

Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology

- Treatment with Selinexor Demonstrated Several Potential Clinical Advantages Compared to Placebo, Including Reduction in Pain, Longer Time to Marked Clinical Deterioration of Pain and Longer Median Time to Next Treatment -
Show more

Karyopharm Therapeutics Frequently Asked Questions

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Who are Karyopharm Therapeutics key executives?

    Karyopharm Therapeutics's key executives are Sharon Shacham, Garen Bohlin and Brian Austad.

  • How many employees does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 464 employees.

  • What is Karyopharm Therapeutics revenue?

    Latest Karyopharm Therapeutics annual revenue is $108.1 m.

  • What is Karyopharm Therapeutics revenue per employee?

    Latest Karyopharm Therapeutics revenue per employee is $232.9 k.

  • Who are Karyopharm Therapeutics competitors?

    Competitors of Karyopharm Therapeutics include Jiangsu Hansoh Pharmaceutical Group, Takeda Oncology and Celltrion Healthcare.

  • Where is Karyopharm Therapeutics headquarters?

    Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.

  • Where are Karyopharm Therapeutics offices?

    Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.

  • How many offices does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 3 offices.